Fig. 7: LSKL administration decreases excitatory synapse and glutamate levels. | Cell Death Discovery

Fig. 7: LSKL administration decreases excitatory synapse and glutamate levels.

From: Increased thrombospondin-1 levels contribute to epileptic susceptibility in neonatal hyperthermia without seizures via altered synaptogenesis

Fig. 7

Gray bands and normalized gray values of TSP-1/TGF-β1 (A–C), PSD-95/synapsin I (D–F) and VGLUT1 (G, H) at 24 hours and 3 days (n = 4/group). I, J Number of positive PSD-95 signals and representative immunohistochemical results of PSD-95 (green) in EC at 3 days (scale bar = 3 μm, n = 4/group). K, L Immunohistochemistry results of VGLUT1 (green) in EC at 3 days (scale bar = 10 μm, n = 4/group). M, N Representative immunohistochemical results of CAMKII (red) in EC at 3 days (scale bar = 10 μm, n = 4/group). Blue, DAPI. O Ratio of normalized power spectra intensity of beta waves (n = 5/group) and (P) content of glutamate (n = 6/group) at 3 days. Mean ± SEMs were presented. *P < 0.05, **P < 0.01, ***P < 0.001 vs saline groups (Unpaired T-test).

Back to article page